Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03180593 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

A Phase 4 study of Blood Pressure and Hypertension Complicated, sponsored by Trinity Hypertension & Metabolic Research Institute.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT03180593 is a Phase 4 study of Blood Pressure and Hypertension Complicated that has completed, run by Trinity Hypertension & Metabolic Research Institute. The registered enrollment target is 30 participants, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03180593, a Phase 4 study of Blood Pressure and Hypertension Complicated, has completed, sponsored by Trinity Hypertension & Metabolic Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.

Interventions

  • DRUG Valsartan 80 mg

Study Locations (1)

Texas

  • Trinity Hypertension & Metabolic Research Institute - Carrollton

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-02-07
Est. Completion 2018-01-25
Phase Phase 4

What the Registry Record Tells You About NCT03180593

The ClinicalTrials.gov registry entry for NCT03180593 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (90% lower). The listed sponsor is Trinity Hypertension & Metabolic Research Institute, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Blood Pressure appearing as the primary indexed condition, and to 1 intervention - of which Valsartan 80 mg is the first listed.

NCT03180593 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03180593 about?

NCT03180593 is a clinical study titled "Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH". To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.

What is the current status of trial NCT03180593?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2017-02-07. Estimated completion is 2018-01-25.

What conditions does trial NCT03180593 study?

This clinical trial studies the following conditions: Blood Pressure, Hypertension Complicated, Hypertrophy, Left Ventricular.

What interventions are being tested in trial NCT03180593?

The interventions under investigation include: Valsartan 80 mg (DRUG).

Who is sponsoring clinical trial NCT03180593?

This trial is sponsored by Trinity Hypertension & Metabolic Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03180593 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blood Pressure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.